摘要
目的探讨选择性环氧合酶-2(COX-2)抑制剂塞来昔布对体内胃癌生长的影响及作用机制。方法建立裸鼠胃癌模型,20只裸小鼠随机分为2组,对照组隔日腹腔注射生理盐水,塞来昔布组隔日腹腔注射塞来昔布30mg/kg,采用免疫组化法检测微血管密度(MVD),采用半定量-TRAP银染法检测端粒酶活性,流式细胞仪检测细胞周期、细胞凋亡率。结果塞来昔布组肿瘤生长明显受抑制,抑瘤率为61.3%,与对照组相比,差异有显著性(P<0.05);流式细胞仪检测到凋亡峰,细胞阻滞于G0/G1期。同时它也显著抑制胃癌细胞的端粒酶活性,肿瘤组织中的MVD较对照组显著降低。结论塞来昔布通过诱导细胞凋亡,降低端粒酶活性,减少血管生成,从而抑制胃癌生长。这可能是COX-2抑制剂塞来昔布体内抗胃癌的机制。
Objective To study the effects of celecoxib, a selective COX-2 inhibitor, on gastric cancer in vivo and to explore its anti-neoplasm mechanism. Methods Twenty mice xenograft models with SGC-7901 human gastric cancer cell were established and randomly divided into two groups. The mice of treated groups were administered with selective COX-2 inhibitor celecoxib. The expression of CD 34 was examined by immunohistochemistry to evaluate microvessel density. Telomerase activity was detected by semi-TRAP assay. Flow cytometry was adopted to examine apoptotic rate and cell cycle. Results Celecoxib inhibited significantly the growth of xenograft and elevated the inhibiting rate （ P 〈 0.05 ） as compared with control grpups. The apoptotic peak was detected with FCM and cells were blocked in G0/G1 stage. The telomerase activity was significantly inhibited. Conclusion COX-2 inhibitor celecoxib has anticancer effects to gastric cancer in vivo by inducing apoptosis,inhibiting telomerase activity and reducing angiogenesis. We conclude that the results may indicate the mechanisms underlying the anti-cancer effect of COX-2 inhibitor.
出处
《临床消化病杂志》
2006年第5期282-285,共4页
Chinese Journal of Clinical Gastroenterology
基金
青岛市卫生局科研基金资助项目(2004-WSZd005)
关键词
胃癌
环氧合酶-2
端粒酶
凋亡
血管生成
Gastric cancer
Cyclooxygenase-2
Telomerase
Apoptosis
Angiogenesis
